The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
"I think (rate cuts) will help, but whether they're going to be sufficient to counter the negative trade pressures and global growth slowdown and impact is debatable," one...Central Banksread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
China has used both monetary and fiscal measures to lift economic activity as its trade war with the U.S. looks set to intensify in the coming months.China Economyread more
The two countries want to smash the civil aerospace duopoly enjoyed by Airbus and Boeing.Aerospace & Defenseread more
Federal Reserve Chairman Jerome Powell is set to deliver his annual speech on Friday at the Jackson Hole, Wyoming symposium, where he's expected to provide more clarity on the...Asia Marketsread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
U.S. and Asian investors poured $3.7 billion into U.K. tech start-ups in the first seven months of 2019, research shows.Technologyread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Secretary of State Mike Pompeo privately told business executives and free traders that the trade war could end by the 2020 election and that hurdles to an immediate agreement...2020 Electionsread more
Market bull Jeff Saut told CNBC on Tuesday that the lows are in and the market is headed "much higher."Marketsread more
Bayer on Wednesday said it would need more time to wrap up its takeover of seeds company Monsanto after the drugmaker reported lower than expected fourth-quarter earnings which were hit by pesticide pricing pressures in Brazil.
The Monsanto deal will now close before the end of June, Bayer said, compared with previous ambitions to finish it early in 2018, but negotiations with antitrust authorities in jurisdictions such as Europe, Russia and the United States are dragging on.
"Operationally, 2017 was a year of ups and downs," Chief Executive Werner Baumann said after the company reported a 1.3 percent fall in fourth-quarter adjusted core earnings, slightly worse than expected by analysts, and flagged stagnant earnings this year.
Bayer's shares dropped 3.4 percent, hitting their lowest in almost 15 months.
"We see this full-year set of numbers as disappointing and guidance for 2018 uninspiring," said Bryan Garnier analyst Eric Le Berrigaud.
The $63.5 billion Monsanto deal will boost Bayer's agriculture sales to the same level as its core healthcare business, but the acquisition has not been universally popular among shareholders, many of which are critical of Bayer's drug pipeline as being too weak.
Bayer has already pledged to sell certain seed and herbicide assets for 5.9 billion euros ($7 billion) to BASF to help to gain approval for the Monsanto deal. Bayer said on Wednesday additional concessions to antitrust regulators would include the sale of its vegetable seeds business, confirming a Reuters report.
Bayer's adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) came in at 1.78 billion euros ($2.18 billion) for the quarter, slightly lower than the average forecast by analysts of 1.8 billion euros.
Weak overseas currencies weighed on the euro-value of products sold in foreign markets, leading to a currency-related hit of about 100 million euros during the quarter.
Bayer warned last year that poor sales in Brazil had inflated inventory levels at distributors, forcing it to grant discounts and to buy back stocks, also in the fourth quarter.
"We are now seeing that the measures are taking effect," Baumann said. As a result, EBITDA before special items at the Crop Science division would likely see a medium to high single-digit percentage gain in 2018, not yet taking Monsanto into account.
For the group, the earnings gauge was set to be roughly flat this year, held back by a 300 million euro negative impact from a rebuke by the U.S. healthcare watchdog over how it handled production of some drugs at its Leverkusen, Germany headquarters.